文献速递临床试验与 GCP

头盔无创通气治疗COVID-19患者(Helmet-COVID):一项随机对照试验的统计分析计划

Helmet noninvasive ventilation for COVID-19 patients (Helmet-COVID): statistical analysis plan for a randomized controlled trial.
PubMed 文献 · Trials · 2022-02-02

本文为Helmet-COVID多中心随机对照试验的统计分析计划,计划纳入320例成人ICU的COVID-19急性低氧性呼吸衰竭患者,随机分配至头盔无创通气联合常规治疗组或单纯常规治疗组,主要结局为随机化后28天内全因死亡。试验把握度80%检测28天死亡率从40%降至25%的15%绝对风险降低,采用卡方检验意向性分析,报告相对危险度和95%置信区间。截至2021年8月1日,已从沙特阿拉伯和科威特的7个中心入组252例患者。

要点

  • 纳入标准:疑似或确诊COVID-19、急性低氧性呼吸衰竭,PaO2/FiO2<200(补氧流量≥10 L/min下)。
  • 主要结局为随机化后28天内全因死亡,把握度80%检测从40%到25%的绝对风险降低。
  • 截至2021年8月1日,7个中心已入组252例,预计2021年11月完成入组。

核心结论

  • 本统计分析计划为Helmet-COVID试验提供分析框架,该试验预计2021年11月完成入组。

研究设计与样本

  • 多中心随机对照试验,计划纳入320例成人ICU患者(年龄≥14岁或按当地标准),随机分配至头盔无创通气联合常规治疗组或单纯常规治疗组。
  • 常规治疗可包括面罩无创通气、经鼻高流量氧疗或标准氧疗。
  • 主要结局采用意向性分析,卡方检验比较两组,报告相对危险度和95%置信区间。

主要发现

  • 试验把握度80%检测28天死亡率从40%降至25%的15%绝对风险降低。
  • 首例患者于2021年2月8日入组;截至2021年8月1日,已从沙特阿拉伯和科威特的7个中心入组252例患者。

关键数值与推荐

  • 纳入标准:疑似或确诊COVID-19,急性低氧性呼吸衰竭,动脉血氧分压与吸入氧浓度比<200, despite supplemental oxygen with a partial/non-rebreathing mask at a flow rate of 10 L/min or higher。
  • 主要结局:随机化后28天内全因死亡。
  • 样本量:320例成人ICU患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Noninvasive respiratory support is frequently needed for patients with acute hypoxemic respiratory failure due to coronavirus disease 19 (COVID-19). Helmet noninvasive ventilation has multiple advantages over other oxygen support modalities but data about effectiveness are limited. METHODS: In this multicenter randomized trial of helmet noninvasive ventilation for COVID-19 patients, 320 adult ICU patients (aged ≥14 years or as per local standards) with suspected or confirmed COVID-19 and acute hypoxemic respiratory failure (ratio of arterial oxygen partial pressure to fraction of inspired oxygen < 200 despite supplemental oxygen with a partial/non-rebreathing mask at a flow rate of 10 L/min or higher) will be randomized to helmet noninvasive ventilation with usual care or usual care alone, which may include mask noninvasive ventilation, high-flow nasal oxygen, or standard oxygen therapy. The primary outcome is death from any cause within 28 days after randomization. The trial has 80% power to detect a 15% absolute risk reduction in 28-day mortality from 40 to 25%. The primary outcome will be compared between the helmet and usual care group in the intention-to-treat using the chi-square test. Results will be reported as relative risk and 95% confidence interval. The first patient was enrolled on February 8, 2021. As of August 1, 2021, 252 patients have been enrolled from 7 centers in Saudi Arabia and Kuwait. DISCUSSION: We developed a detailed statistical analysis plan to guide the analysis of the Helmet-COVID trial, which is expected to conclude enrollment in November 2021. TRIAL REGISTRATION: ClinicalTrials.gov NCT04477668 . Registered on July 20, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Arabi Y, Aldekhyl S, Al Qahtani S, et al. Helmet noninvasive ventilation for COVID-19 patients (Helmet-COVID): statistical analysis plan for a randomized controlled trial. Trials. 2022. PMID: 35109898. doi:10.1186/s13063-021-05988-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。